Rapport Therapeutics CEO Abraham Ceesay disposes of USD 87,135.01 in common shares

RAPP•2026-09-24

CEO Abraham Ceesay sold 2,210 Rapport Therapeutics common shares on Sept. 23, 2026, for a total of USD 87,135.01.

1. Share sale

Ceesay sold the shares at prices of USD 39.0523, USD 39.8602 and USD 41.05. His directly held stake fell to 456,767 shares. The filing also reported 81,729 shares held through the Ceesay Family Irrevocable Trust and 20,729 shares held through the Dorothy Ceesay Irrevocable Trust.

Sources

Rapport Therapeutics CEO Abraham Ceesay disposes of USD 87,135.01 in common shares

Sec

Rapport Therapeutics CEO Abraham Ceesay disposes of USD 87,135.01 in common shares

1. Share sale

Related News

Iridium stockholders voted to adopt Rocket Lab merger agreement at special meeting

The Day Ahead — North America, September 25

Jin Medical closes US$159.42 million VIE control acquisition of Huaxia Qiying

Sources

Rapport Therapeutics CEO Abraham Ceesay disposes of USD 87,135.01 in common shares

Giftify VP Sales Timothy William Miller disposes of 1,000 common shares for $1,000

U.S. Fed weekly balance sheet